Neurology is one of the typical disciplines where personalized medicine has been recently becoming an important part of clinical practice. In this article, the brief overview and a number of examples of the use of biomarkers and personalized medicine in neurology are described. The various issues in neurology are described in relation to the personalized medicine and diagnostic, prognostic as well as predictive blood and cerebrospinal fluid biomarkers. Such neurological domains discussed in this work are neuro-oncology and primary brain tumors glioblastoma and oligodendroglioma, cerebrovascular diseases focusing on stroke, neurodegenerative disorders especially Alzheimer's and Parkinson's diseases and demyelinating diseases such as multiple sclerosis. Actual state of the art and future perspectives in diagnostics and personalized treatment in diverse domains of neurology are given.

Central Imunoanalytical Laboratory Faculty Hospital Plzen E Benese 13 305 99 Plzen Czech Republic

Department of Histology and Embryology Charles University Prague Husova 3 301 66 Plzen Czech Republic ; Biomedical Centre Faculty of Medicine in Plzen Charles University Prague Husova 3 301 66 Plzen Czech Republic

Department of Neurology Faculty of Medicine in Plzen Charles University Prague Husova 3 301 66 Plzen Czech Republic ; Department of Neurology Faculty Hospital Plzen E Benese 13 305 99 Plzen Czech Republic

Zobrazit více v PubMed

Gottlieb S. Personalised medicine comes a step closer for asthma. BMJ. 2000;321:724. doi: 10.1136/bmj.321.7263.724. PubMed DOI PMC

Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons. Future Directions Drug Metab Rev. 2008;40:187–224. doi: 10.1080/03602530801952864. PubMed DOI PMC

Golubnitschaja O, Costigliola V, EPMA General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14. doi: 10.1186/1878-5085-3-14. PubMed DOI PMC

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi: 10.1007/s00401-007-0243-4. PubMed DOI PMC

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020. PubMed DOI PMC

Polivka J, Jr, Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res. 2012;32:2935–2946. PubMed

Polivka J, Pesta M, Janku F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn. 2015;15:1631–1644. doi: 10.1586/14737159.2015.1110021. PubMed DOI PMC

Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016;122:189–97. doi: 10.1002/cncr.29742. PubMed DOI

Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review) Int J Oncol. 2015;47:417–428. PubMed PMC

Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 2013;14:e370–e379. doi: 10.1016/S1470-2045(13)70168-2. PubMed DOI

Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. doi: 10.1056/NEJMoa043331. PubMed DOI

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116–121. doi: 10.1093/neuonc/nop020. PubMed DOI PMC

Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011;17:641–649. doi: 10.1016/j.molmed.2011.06.001. PubMed DOI PMC

Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. doi: 10.1126/science.1164382. PubMed DOI PMC

Yan H, Parsons DW, Jin G, Mclendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. doi: 10.1056/NEJMoa0808710. PubMed DOI PMC

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–474. doi: 10.1007/s00401-009-0561-9. PubMed DOI

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150–4. doi: 10.1200/JCO.2009.21.9832. PubMed DOI

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–718. doi: 10.1007/s00401-010-0781-z. PubMed DOI

Polivka J, Polivka J, Jr, Rohan V, Topolcan O. Glioblastoma multiforme—a review of pathogenesis, biomarkers and therapeutic perspectives. Cesk Slov Neurol N. 2013;76/109:575–583.

Polivka J, Polivka J, Jr, Rohan V, Pesta M, Repik T, Pitule P, et al. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in west bohemia. Biomed Res Int. 2014;2014:735659. doi: 10.1155/2014/735659. PubMed DOI PMC

Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q, et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget. 2015;6:17354–17365. doi: 10.18632/oncotarget.4008. PubMed DOI PMC

Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JWM, Boots-Sprenger SHE, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014;16:1263–1273. doi: 10.1093/neuonc/nou005. PubMed DOI PMC

Polivka J, Polivka J, Rohan V, Topolcan O. New treatment paradigm for patients with anaplastic oligodendroglial tumors. Anticancer Res. 2014;34:1587–1594. PubMed

Van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–2722. doi: 10.1200/JCO.2005.04.6078. PubMed DOI

Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995;54:91–95. doi: 10.1097/00005072-199501000-00011. PubMed DOI

Cahill DP, Louis DN, Cairncross JG. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol. 2015;4:287–294. doi: 10.2217/cns.15.32. PubMed DOI PMC

Intergroup Radiation Therapy Oncology Group Trial 9402. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–2714. doi: 10.1200/JCO.2005.04.3414. PubMed DOI

Van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre J-Y, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50. doi: 10.1200/JCO.2012.43.2229. PubMed DOI

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337–343. doi: 10.1200/JCO.2012.43.2674. PubMed DOI PMC

Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3:95. PubMed PMC

Killock D. CNS cancer: molecular classification of glioma. Nat Rev Clin Oncol. 2015;12:502. doi: 10.1038/nrclinonc.2015.111. PubMed DOI

Polivka J, Polivka J, Repik T, Rohan V, Hes O, Topolcan O. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Anticancer Res. 2016;36:471–476. PubMed

Szymanski FM, Lip GYH, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Opolski G. Stroke Risk Factors Beyond the CHA2DS2-VASc Score: Can We Improve Our Identification of “High Stroke Risk” Patients With Atrial Fibrillation? Am J Cardiol. 2015;116:1781–1788. doi: 10.1016/j.amjcard.2015.08.049. PubMed DOI

Senn R, Elkind MSV, Montaner J, Christ-Crain M, Katan M. Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. Cerebrovasc Disz. 2014;38:395–409. doi: 10.1159/000366470. PubMed DOI

Jickling GC, Sharp FR. Biomarker panels in ischemic stroke. Stroke. 2015;46:915–920. doi: 10.1161/STROKEAHA.114.005604. PubMed DOI PMC

Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009;111:483–495. doi: 10.1016/j.clineuro.2009.04.001. PubMed DOI

Kernagis DN, Laskowitz DT. Evolving role of biomarkers in acute cerebrovascular disease. Ann Neurol. 2012;71:289–303. doi: 10.1002/ana.22553. PubMed DOI

Ren C, Kobeissy F, Alawieh A, Li N, Li N, Zibara K, et al. Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Sci Rep. 2016;6:24588. doi: 10.1038/srep24588. PubMed DOI PMC

Turner RJ, Sharp FR. Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Front Cell Neurosci. 2016;10:56. doi: 10.3389/fncel.2016.00056. PubMed DOI PMC

Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed) 2009;1:200–208. PubMed

Bettermann K. Biomarkers for stroke: in search of fingerprints. J Stroke Cerebrovasc Dis. 2011;20:173–6. doi: 10.1016/j.jstrokecerebrovasdis.2011.02.003. PubMed DOI

Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008;39:2902–9. doi: 10.1161/STROKEAHA.107.511261. PubMed DOI

Sharp FR, Jickling GC, Stamova B, Tian Y, Zhan X, Liu D, et al. Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J Cereb Blood Flow Metab. 2011;31:1513–31. doi: 10.1038/jcbfm.2011.45. PubMed DOI PMC

Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vasc Pharmacol. 2011;55:111–118. doi: 10.1016/j.vph.2011.08.001. PubMed DOI

Li M, Zhang J. Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases. Biomed Res Int. 2015;2015:730535. PubMed PMC

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362. doi: 10.1056/NEJMoa0809171. PubMed DOI

Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–2293. doi: 10.1056/NEJMoa044503. PubMed DOI

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690–1698. doi: 10.1001/jama.287.13.1690. PubMed DOI

SEARCH Collaborative Group. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008;359:789–799. doi: 10.1056/NEJMoa0801936. PubMed DOI

Mandel SA, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA J. 2010;1:273–292. doi: 10.1007/s13167-010-0036-z. PubMed DOI PMC

Golubnitschaja O. Neurodegeneration: accelerated ageing or inadequate healthcare? EPMA J. 2010;1:211–215. doi: 10.1007/s13167-010-0030-5. PubMed DOI PMC

Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111–128. PubMed PMC

Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer’s disease therapeutics. Front Neurol. 2015;6:186. doi: 10.3389/fneur.2015.00186. PubMed DOI PMC

Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases. Mol Diagn Ther. 2011;15:83–102. doi: 10.1007/BF03256398. PubMed DOI

Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–144. doi: 10.1038/nrneurol.2010.4. PubMed DOI

Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer’s disease - current concepts. Mol Neurodegener. 2013;8:20. doi: 10.1186/1750-1326-8-20. PubMed DOI PMC

Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci. 2015;9:345. doi: 10.3389/fnins.2015.00345. PubMed DOI PMC

Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement. 2008;4:38–48. doi: 10.1016/j.jalz.2007.08.006. PubMed DOI

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801–805. doi: 10.1212/WNL.57.5.801. PubMed DOI

Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol. 2001;49:808–10. doi: 10.1002/ana.1061. PubMed DOI

Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem. 2005;280:17458–63. doi: 10.1074/jbc.M414176200. PubMed DOI

Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al. The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem. 1990;265:15977–83. PubMed

Borroni B, Colciaghi F, Corsini P, Akkawi N, Rozzini L, Del Zotto E, et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol Sci. 2002;23:207–10. doi: 10.1007/s100720200042. PubMed DOI

Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 2002;59:71–5. doi: 10.1001/archneur.59.1.71. PubMed DOI

Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641–50. doi: 10.1016/j.neurobiolaging.2003.12.023. PubMed DOI

Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977–83. doi: 10.1212/01.WNL.0000128091.92139.0F. PubMed DOI

He S, Liu D, Wang S, Xia Y. Expression of apolipoprotein E in Alzheimer’s disease and its significance. Zhonghua Bing Li Xue Za Zhi. 2005;34:556–60. PubMed

Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: a population-based study of African Americans. Neurology. 2000;54:240–2. doi: 10.1212/WNL.54.1.240. PubMed DOI

Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease. Neuroreport. 2000;11:1959–62. doi: 10.1097/00001756-200006260-00030. PubMed DOI

Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer’s disease using metabolomics technology. J Lipid Res. 2012;53:567–76. doi: 10.1194/jlr.M022376. PubMed DOI PMC

Li F-J, Shen L, Ji H-F. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer’s disease: a meta-analysis. J Alzheimers Dis. 2012;31:253–8. PubMed

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–1222. doi: 10.1056/NEJM199704243361704. PubMed DOI

Mangialasche F, Solomon A, Kåreholt I, Hooshmand B, Cecchetti R, Fratiglioni L, et al. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol. 2013;48:1428–35. doi: 10.1016/j.exger.2013.09.006. PubMed DOI

Lu’o’ng KVQ, Nguyen LTH. The role of vitamin D in Alzheimer’s disease: possible genetic and cell signaling mechanisms. Am J Alzheimers Dis Other Demen. 2013;28:126–36. doi: 10.1177/1533317512473196. PubMed DOI PMC

Praticò D, Clark CM, Liun F, Rokach J, Lee VY-M, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–6. doi: 10.1001/archneur.59.6.972. PubMed DOI

Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol. 2002;52:175–9. doi: 10.1002/ana.10272. PubMed DOI

Dou C, Zhang J, Sun Y, Zhao X, Wu Q, Ji C, et al. The association of ACT-17 A/T polymorphism with Alzheimer’s disease: a meta-analysis. Curr Alzheimer Res. 2013;10:63–71. PubMed

Zhang J, Jr, Shi S., Sr A literature review of AD7c-ntp as a biomarker for Alzheimer’s disease. Ann Indian Acad Neurol. 2013;16:307–9. doi: 10.4103/0972-2327.116902. PubMed DOI PMC

Fennema-Notestine C, Panizzon MS, Thompson WR, Chen C-H, Eyler LT, Fischl B, et al. Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis. 2011;26(Suppl 3):49–60. PubMed PMC

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C. Alzheimer’s Disease Neuroimaging Initiative. Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Aging. 2012;33(1124):e31–41. PubMed PMC

Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040–8. doi: 10.1001/archneurol.2011.167. PubMed DOI PMC

Mosconi L, Tsui W-H, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64:1860–1867. doi: 10.1212/01.WNL.0000163856.13524.08. PubMed DOI

Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510. doi: 10.1007/s00259-005-1762-7. PubMed DOI

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–1411. doi: 10.1001/archneurol.2011.150. PubMed DOI

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057–1065. doi: 10.1016/S1474-4422(12)70227-2. PubMed DOI PMC

Schapira AHV. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26:395–400. doi: 10.1097/WCO.0b013e3283633741. PubMed DOI PMC

Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain J Neurol. 1991;114(Pt 5):2283–2301. doi: 10.1093/brain/114.5.2283. PubMed DOI

Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A. Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. 2012;46:508–526. doi: 10.1016/j.nbd.2011.10.019. PubMed DOI

Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson’s disease. Parkinsons Dis. 2011;2011:708404. PubMed PMC

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230–40. doi: 10.1016/S1474-4422(11)70014-X. PubMed DOI

Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain J Neurol. 2011;134:e178. doi: 10.1093/brain/awr015. PubMed DOI PMC

Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, et al. Phosphorylated α-synuclein in Parkinson’s disease. Sci Transl Med. 2012;4:121–20. PubMed PMC

Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiol Dis. 2015;80:29–41. doi: 10.1016/j.nbd.2015.05.004. PubMed DOI

Im SY, Kim YE, Kim YJ. Genetics of progressive supranuclear palsy. J Mov Disord. 2015;8:122–9. doi: 10.14802/jmd.15033. PubMed DOI PMC

El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006;20:419–25. doi: 10.1096/fj.03-1449com. PubMed DOI

Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 2008;7:501–7. doi: 10.1016/j.autrev.2008.04.010. PubMed DOI

Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 2008;167:90–5. doi: 10.1093/aje/kwm260. PubMed DOI

Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease. J Neurol. 2010;257:540–5. doi: 10.1007/s00415-009-5357-2. PubMed DOI

Parker WD, Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 1989;26:719–23. doi: 10.1002/ana.410260606. PubMed DOI

Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain J Neurol. 1992;115(Pt 2):333–42. doi: 10.1093/brain/115.2.333. PubMed DOI

Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, et al. Altered redox state of platelet coenzyme Q10 in Parkinson’s disease. J Neural Transm (Vienna) 2000;107:41–8. doi: 10.1007/s007020050003. PubMed DOI

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716–23. doi: 10.1001/archneur.2008.65.6.nct70003. PubMed DOI PMC

Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69:655–63. doi: 10.1002/ana.22271. PubMed DOI PMC

Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140–149. doi: 10.1016/j.tig.2015.01.004. PubMed DOI

Oeda T, Umemura A, Mori Y, Tomita S, Kohsaka M, Park K, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson’s disease. Neurobiol Aging. 2015;36:3306–13. doi: 10.1016/j.neurobiolaging.2015.08.027. PubMed DOI

Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci. 2003;4:727–738. doi: 10.1038/nrn1199. PubMed DOI

Azuma R, Ishikawa K, Hirata K, Hashimoto Y, Takahashi M, Ishii K, et al. A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration. Mov Disord. 2015;30:1964–7. doi: 10.1002/mds.26345. PubMed DOI

Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson’s disease (recent update) Neurochem Int. 2013;63:201–229. doi: 10.1016/j.neuint.2013.06.005. PubMed DOI

Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WRW. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson’s disease. Mov Disord. 2007;22:382–6. doi: 10.1002/mds.21288. PubMed DOI

Wu G, Shen Y-J, Huang M-H, Xing Z, Liu Y, Chen J. Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. AJR Am J Roentgenol. 2016;206:385–9. doi: 10.2214/AJR.14.14052. PubMed DOI

Brooks DJ. Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord. 2009;24(Suppl 2):S742–7. doi: 10.1002/mds.22581. PubMed DOI

Garibotto V, Montandon ML, Viaud CT, Allaoua M, Assal F, Burkhard PR, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med. 2013;38:e112–7. doi: 10.1097/RLU.0b013e318279b991. PubMed DOI

Tripathi M, Tripathi M, Damle N, Kushwaha S, Jaimini A, D’Souza MM, et al. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT. Neuroradiol J. 2014;27:13–21. doi: 10.15274/NRJ-2014-10002. PubMed DOI PMC

Löhle M, Mende J, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, et al. Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications. Neurology. 2016;86:231–240. doi: 10.1212/WNL.0000000000002286. PubMed DOI

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57:168–175. doi: 10.1002/ana.20338. PubMed DOI

Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. [99mTc] TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology. 2005;64:1716–1720. doi: 10.1212/01.WNL.0000161874.52302.5D. PubMed DOI

Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–32. PubMed

Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in Parkinson’s disease: Practical considerations and future directions. Expert Rev Neurother. 2016;16:389–99. doi: 10.1586/14737175.2016.1158103. PubMed DOI

Nakum S, Cavanna AE. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson’s disease following dopaminergic therapy: A systematic literature review. Parkinsonism Relat Disord. 2016;25:10–6. doi: 10.1016/j.parkreldis.2016.02.017. PubMed DOI

Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597–606. doi: 10.1038/nrneurol.2015.157. PubMed DOI

Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471–482. doi: 10.1038/nrneurol.2015.106. PubMed DOI

Owens GP, Bennett JL, Lassmann H, O’Connor KC, Ritchie AM, Shearer A, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009;65:639–649. doi: 10.1002/ana.21641. PubMed DOI PMC

Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255:1023–1031. doi: 10.1007/s00415-008-0827-5. PubMed DOI

Brettschneider J, Tumani H, Kiechle U, Muche R, Richards G, Lehmensiek V, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One. 2009;4:e7638. doi: 10.1371/journal.pone.0007638. PubMed DOI PMC

Margaritella N, Mendozzi L, Garegnani M, Nemni R, Colicino E, Gilardi E, et al. Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS? BMC Neurol. 2012;12:80. doi: 10.1186/1471-2377-12-80. PubMed DOI PMC

Schlaeger R, D’Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol. 2012;123:406–10. doi: 10.1016/j.clinph.2011.06.021. PubMed DOI

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21:1013–1024. doi: 10.1177/1352458514568827. PubMed DOI

Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain J Neurol. 2015;138:1863–74. doi: 10.1093/brain/awv105. PubMed DOI

Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J. 2013;4:4. doi: 10.1186/1878-5085-4-4. PubMed DOI PMC

Behrens JR, Rasche L, Gieß RM, Pfuhl C, Wakonig K, Freitag E, et al. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol. 2016;23:62–67. doi: 10.1111/ene.12788. PubMed DOI

Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2:e167. doi: 10.1212/NXI.0000000000000167. PubMed DOI PMC

Kimbrough DJ, Mealy MA, Simpson A, Levy M. Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e4. doi: 10.1212/NXI.0000000000000004. PubMed DOI PMC

Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605–12. doi: 10.1177/1352458512460605. PubMed DOI

Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009;15:848–53. doi: 10.1177/1352458509104591. PubMed DOI

Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of “no evidence of disease activity” in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3–13. doi: 10.1177/1756285614560733. PubMed DOI PMC

Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354. doi: 10.1007/s11940-015-0354-5. PubMed DOI

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15(6):574–84. doi: 10.1016/S1474-4422(16)00068-5. PubMed DOI

Schneider E, Zimmermann H, Oberwahrenbrock T, Kaufhold F, Kadas EM, Petzold A, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One. 2013;8:e66151. doi: 10.1371/journal.pone.0066151. PubMed DOI PMC

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678–88. doi: 10.1177/1352458514567216. PubMed DOI PMC

Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol. 2005;166:180–8. doi: 10.1016/j.jneuroim.2005.06.003. PubMed DOI

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology. 2000;54:2055–60. doi: 10.1212/WNL.54.11.2055. PubMed DOI

Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184–1191. doi: 10.1016/S0140-6736(03)14541-2. PubMed DOI

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001;256:141–52. doi: 10.1016/S0022-1759(01)00434-3. PubMed DOI

Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73:372–377. doi: 10.1212/WNL.0b013e3181b04c98. PubMed DOI

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006;12:47–57. doi: 10.1191/135248506ms1245oa. PubMed DOI

Tian W, Zhu T, Zhong J, Liu X, Rao P, Segal BM, et al. Progressive decline in fractional anisotropy on serial DTI examinations of the corpus callosum: a putative marker of disease activity and progression in SPMS. Neuroradiology. 2012;54:287–97. doi: 10.1007/s00234-011-0885-8. PubMed DOI

Brown RA, Narayanan S, Arnold DL. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage. 2012;66C:103–109. PubMed

Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2002;23:985–988. PubMed PMC

Rashid W, Davies GR, Chard DT, Griffin CM, Altmann DR, Gordon R, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry. 2006;77:51–55. doi: 10.1136/jnnp.2005.068338. PubMed DOI PMC

Mcguigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117–125. PubMed PMC

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflammation. 2016;3:e195. doi: 10.1212/NXI.0000000000000195. PubMed DOI PMC

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865–71. doi: 10.1212/WNL.0b013e3182a351fb. PubMed DOI

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2015. doi:10.1177/1352458515607651. PubMed

Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–64. doi: 10.1111/cei.12271. PubMed DOI PMC

Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62. doi: 10.1212/NXI.0000000000000062. PubMed DOI PMC

Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e163. doi: 10.1212/NXI.0000000000000163. PubMed DOI PMC

Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2:e110. doi: 10.1212/NXI.0000000000000110. PubMed DOI PMC

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach

Predictive and individualized management of stroke-success story in Czech Republic

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme